What does CUSIP 10501E201 represent in this 13F holders report?

CUSIP 10501E201 is the security identifier for BCLI - BRAINSTORM CELL THERAPEUTICS - COM NEW used to aggregate holder disclosures.

How many institutions held BCLI - BRAINSTORM CELL THERAPEUTICS - COM NEW in Q1 2024?

44 institutional investors reported BCLI - BRAINSTORM CELL THERAPEUTICS - COM NEW for Q1 2024. Use the holders table for investor-level position and value details.

BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI)

CUSIP: 10501E201

Q1 2024 13F Holders as of 31 Mar 2024

Security type / class: Equity / COM NEW
Total 13F shares: 3,881,982
Total 13F value: $2,192,251
Share change: +82,618
Put/Call ratio: 1.3%
SEC-reported price per share: $0.56
Number of holders: 44
Value change: +$82,765
Number of buys: 12
Number of sells: 15

Security key

10501E201

Report period

Q1 2024

Institutions

Top holders

BCLI full security history Ownership snapshot Full 13F holder table BRAINSTORM CELL THERAPEUTICS INC. SEC filings BRAINSTORM CELL THERAPEUTICS INC. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of BCLI - BRAINSTORM CELL THERAPEUTICS - COM NEW (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Sankesh Abbhi

Disclosed value leader

Sankesh Abbhi

Comparable rows

0/15

Latest evidence

31 Dec 2023

3/4/5 13F Highest disclosed value: $3,860,181 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Sankesh Abbhi has the largest disclosed position value at $3.86M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Sankesh Abbhi's linked filing trail.

Disclosed position value Top 5

Sankesh Abbhi $3.86M

Ralph Dr. Kern $396.2K

VANGUARD GROUP INC $388.6K

Malcolm S. Taub $137.2K

BlackRock Finance, Inc. $127.3K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Sankesh Abbhi	3/4/5 Director 3/4/5	— class O/S missing	$3,860,181 2,175,853 shares	—	10 Dec 2021
Ralph Dr. Kern	3/4/5 COO and Chief Medical Officer 3/4/5	— class O/S missing	$396,174 223,310 shares	—	06 Mar 2022
VANGUARD GROUP INC	13F Company 13F	— class O/S missing	$388,564 1,423,310 shares	—	31 Dec 2023
Malcolm S. Taub	3/4/5 Director 3/4/5	— class O/S missing	$137,195 77,332 shares	—	15 Dec 2021
BlackRock Finance, Inc.	13F Company 13F	— class O/S missing	$127,316 466,355 shares	—	31 Dec 2023
GEODE CAPITAL MANAGEMENT, LLC	13F Company 13F	— class O/S missing	$97,512 357,041 shares	—	31 Dec 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

3,881,982

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q1 2024 Across Filers

Q1 2024 holders

Holder diff

Investor	Q1 2024 Shares	Q1 2024 Shares	Share Diff	Share Chg %	Q1 2024 value	Q1 2024 value	Value change	Value Chg %